The Cigna Group account plan
global health insurance provider
At a glance
The Cigna Group is a U.S. health company (Evernorth, Cigna Healthcare) with 2025 revenues of $274,900 million and about 67,700 employees.
The Cigna Group, headquartered in Bloomfield, Connecticut, combines a pharmacy and health services business, Evernorth Health Services, with a health benefits business, Cigna Healthcare. It sells pharmacy benefit management, specialty pharmacy, care services and employer medical plans to health plans, employers, unions and government programmes; revenues from U.S. external customers were 98% of the total in 2025. Total 2025 revenues were $274,900 million (+11%), shareholders' net income $5,957 million and adjusted income from operations $8,014 million ($29.84 per share). It employed approximately 67,700 people at the end of 2025 and served more than 185 million customer relationships. Brian Evanko led the group as President and CEO by July 2026; David M. Cordani was Chairman and CEO at the time of the 10-K in February 2026.
Business units
Evernorth Health Services
about 86% of 2025 adjusted revenues before eliminations ($234,953 million)Pharmacy and health services sold to health plans, employers, government programmes and providers, and embedded in Cigna Healthcare plans. 2025 adjusted revenues rose 16% and pre-tax adjusted income was $7,221 million; it is about 60% of group earnings. Major clients include Centene, Prime Therapeutics and the TRICARE programme.
Pharmacy Benefit Services
$132,126 million adjusted revenues in 2025Express Scripts claims adjudication, pharmacy networks of more than 65,000 pharmacies, formulary management and home delivery. Q2 2026 pre-tax adjusted income fell 27% to $609 million on large client renewals and the move to Signature, the rebate-free model. Led by Adam Kautzner, President, Evernorth Care Management and Express Scripts.
Specialty and Care Services
$102,827 million adjusted revenues in 2025Accredo specialty pharmacy, CuraScript SD specialty distribution, MDLIVE virtual care and EviCore benefits management. Q2 2026 pre-tax adjusted income rose 22% on specialty volume and biosimilar and specialty generic adoption; it is 37% of group earnings. Led by Matt Perlberg, President, Evernorth Pharmacy and Care Delivery.
Cigna Healthcare
about 17% of 2025 adjusted revenues before eliminations ($47,163 million)Employer medical plans (ASO and insured), stop-loss, dental and behavioral benefits and international health cover, with 18,118 thousand medical customers at end-2025. 2025 revenues fell 11% after the sale of the Medicare businesses to HCSC; Q2 2026 pre-tax adjusted income rose 17% to $1,276 million. U.S. business led by Bryan Holgerson, President, Cigna Healthcare US.
U.S. Healthcare
$35,551 million premiums in 2025Employer plans across National Accounts, Middle Market, Select and Small, plus stop loss; the Individual and Family Plans medical business will be exited as of January 1, 2027. Select market share is 8% with a 10% target by 2030.
International Health
$4,126 million premiums in 2025Global health care for multinational employers and globally mobile individuals, and local health care in China, Singapore, Hong Kong, Spain, India and Middle Eastern countries; about 10% of Cigna Healthcare.
Other Operations
$674 million adjusted revenues in 2025Corporate-owned life insurance, run-off settlement annuity and reinsurance businesses and other non-strategic businesses.
Strategic priorities
- 10% to 14% EPS growth through 2030
- The long-term framework combines 6% to 9% average annual income growth with 4% to 5% EPS accretion from capital deployment, with an adjusted EPS floor of $45 per share by 2030.
- Grow specialty pharmacy
- Specialty is to exceed 40% of group earnings by 2030, with 8% to 12% long-term annual earnings growth and about $20 billion of new distribution revenue by 2030.
- Rebate-free pharmacy benefits (Signature)
- Upfront discounts at the counter for Cigna Healthcare fully insured customers from 2027 and the standard for Evernorth clients from 2028, with at least 50% of members on Signature models by end 2028.
- Employer health plans, Select first
- Cigna Healthcare targets 6% to 9% earnings growth, a 10% Select market share by 2030 and another 10% improvement in unit cost position.
- Productivity and AI
- A $3 billion modernization and productivity programme from 2026 through 2030 covers workflow automation, AI, talent and supplier optimisation, on top of the strategic optimization program targeting at least $500 million of annualized after-tax savings.
Latest results
In Q2 2026 total revenues rose 7% to $71,668 million and adjusted income from operations rose 6% to $2,054 million, or $7.78 per share. Evernorth's adjusted revenues grew 6% to $61,468 million but its pre-tax adjusted income fell 2%, as Specialty and Care Services (+22%) offset Pharmacy Benefit Services (-27%). Cigna Healthcare's pre-tax adjusted income rose 17% with an MCR of 84.5%. Pharmacy customers fell 4% to 118.2 million while medical customers rose 2% to 18.4 million. Full-year 2026 guidance was raised to adjusted income from operations of at least $30.45 per share and reaffirmed at the September 30, 2026 Investor Day.
Investments and deals
- Shields Health Solutions
- In Q3 2025 the company invested $3.5 billion in preferred stock of Shields, which runs specialty pharmacies for over 80 health systems.
- Medicare divestiture
- Medicare Advantage, stand-alone drug plans, supplemental benefits and CareAllies were sold to Health Care Service Corporation on March 19, 2025 for final cash proceeds of $4.9 billion, mostly used for buybacks.
- Technology capex
- Capex was $1.2 billion in 2025 and about $1.3 billion is planned for 2026, mainly technology.
- AI partnerships
- Sierra provides conversational and voice AI, and a collaboration with OpenAI on clinical AI starts with oncology; Pharmacy Forward is expected to cut time to therapy in half.
- Capital return
- About $50 billion of operating cash flow is expected in 2026-2030, with 55% to 60% for buybacks, debt repayment and M&A focused on bolt-ons.
Challenges and risks
- PBM regulation
- The Consolidated Appropriations Act, 2026 requires PBMs to remit 100% of certain rebates and fees to ERISA plan sponsors from August 2028 and adds Part D rules from 2028 and 2029.
- Pressure on Pharmacy Benefit Services earnings
- Large-client renewals through the end of the decade and Signature transition spending weigh on PBS income in 2026 and 2027; one client is about 19% of total revenues.
- Elevated medical cost trends
- Management sees high single digit cost trends driven by brand drug and hospital prices, and assumes elevated trend through 2026 and 2027.
- Lower GLP-1 volumes
- GLP-1 growth is moderating as coverage declines, and the Q2 2026 Evernorth outperformance is expected to be given back in the second half.
- Litigation and AI scrutiny
- Risks include litigation alleging improper use of AI in claims evaluation, cybersecurity, and goodwill and intangibles of about $73.5 billion.
What leadership says
“affordability continues to be the most pronounced problem across the health care space”
“By harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day.”
“This is not about replacing clinicians with technology but helping clinicians spend more time where they can make the greatest difference.”
“We use AI to augment but never to replace clinical expertise.”
Where a supplier can help
- Automation for the $3 billion programme
- The modernization and productivity programme names workflow automation, AI and supplier optimisation, which opens doors for process automation, AI tooling and outsourcing vendors.
- Signature rollout
- Moving clients to the rebate-free model by 2028 needs claims system changes, pharmacy pricing analytics and client communication support.
- Specialty distribution growth
- The target of about $20 billion of new distribution revenue by 2030 and a fifth clean room under construction point to cold-chain logistics, pharmacy automation and compliant facility suppliers.
- Compliance with PBM rules
- The Consolidated Appropriations Act, 2026 remittance and Part D rules call for reporting, audit and transparency tooling for plan sponsors.
- Employer affordability tools
- With affordability the main employer concern and Select growth a priority, benefits navigation, cost transparency and care management solutions fit Cigna Healthcare's offer.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like The Cigna Group?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for fiscal year 2025 (year ended December 31, 2025)
- The Cigna Group is a global health company with two segments: Evernorth Health Services (Pharmacy Benefit Services incl. Express Scripts, and Specialty and Care Services incl. Accredo, CuraScript SD, MDLIVE and EviCore) and Cigna Healthcare (U.S. Healthcare and International Health). About 67,700 employees, more than 185 million customer relationships in more than 30 markets and jurisdictions; 98% of revenues come from U.S. customers.
- FY2025 total revenues $274,900 million (+11%), driven by pharmacy revenues of $216,672 million (+17%); premiums fell 12% to $40,261 million after the sale of the Medicare businesses. Shareholders' net income $5,957 million ($22.18 per share); adjusted income from operations $8,014 million, $29.84 per share (+9%).
- Evernorth adjusted revenues $234,953 million (+16%) and pre-tax adjusted income $7,221 million (+3%, margin 3.1%): Pharmacy Benefit Services $132,126 million / $3,506 million (-2%), Specialty and Care Services $102,827 million / $3,715 million (+8%); 2,222 million adjusted pharmacy claims.
- Cigna Healthcare adjusted revenues $47,163 million (-11%), pre-tax adjusted income $4,153 million (-2%), margin 8.8%, medical care ratio 84.4% (up 120 bps, driven by Individual and Family Plans); 18,118 thousand medical customers, 79% of them ASO (self-funded).
- Portfolio shaping: Medicare Advantage, Part D stand-alone, Medicare supplemental and CareAllies sold to HCSC on March 19, 2025 for $4.9 billion; $3.5 billion invested in Shields Health Solutions preferred stock (specialty pharmacy management for health systems).
- A rebate-free pharmacy benefit model will be used for Cigna Healthcare's fully insured customers from 2027 and become the standard Evernorth model from 2028; contracts with Evernorth's three largest clients (Centene, Prime Therapeutics, the Department of War TRICARE) were renewed or extended through the end of the decade, which weighs on near-term PBS earnings. One pharmacy benefit client was about 19% of revenues.
- Strategic optimization program launched in 2025: $749 million pre-tax cost, at least $500 million of annualized after-tax savings expected. Capex $1.2 billion in 2025, about $1.3 billion planned for 2026 (mainly technology); $3.6 billion of share buybacks in 2025.
- Regulatory pressure on PBMs: the Consolidated Appropriations Act, 2026 requires PBMs to remit 100% of certain rebates and fees to ERISA plan sponsors from August 2028 and delinks Part D PBM pay from list prices from January 2028; enhanced ACA subsidies expired December 31, 2025.
- Leadership at filing: David Cordani Chairman and CEO (CEO since 2009), Brian Evanko President and COO, Ann Dennison CFO; total debt about $31.5 billion, goodwill and intangibles $73.5 billion (47% of assets).
- The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook (earnings release)
- Q2 2026 total revenues $71.7 billion (+7%), driven by both Evernorth Health Services and Cigna Healthcare; shareholders' net income $1.7 billion ($6.29 per share); adjusted income from operations $2.1 billion, $7.78 per share (vs $7.20).
- 2026 outlook raised to adjusted EPS of at least $30.45 (+$0.10); Cigna Healthcare pre-tax adjusted income at least $4,550 million (+$25 million); Evernorth at least $6,900 million unchanged; medical care ratio 83.7% to 84.7%.
- Evernorth adjusted revenues $61,468 million (+6%), pre-tax adjusted income $1,663 million (-2%). Pharmacy Benefit Services income fell 27% to $609 million on large-client contract renewals and customer initiatives; Specialty and Care Services income rose 22% to $1,054 million on specialty volume and generic/biosimilar adoption.
- Cigna Healthcare adjusted revenues $11,728 million (+9%), pre-tax adjusted income $1,276 million (+17%, better U.S. Employer margin); MCR 84.5% vs 83.2%.
- In April 2026 the company announced its exit from the Individual and Family Plans medical business as of January 1, 2027.
- Customer relationships 182.8 million (-3% vs year-end): pharmacy customers 118.2 million (-4%, expected client transitions), medical customers 18.4 million (+2%, Middle and Select markets).
- CEO Brian Evanko credits "harnessing technology, data and AI"; SG&A ratio improved to 4.8% from 5.1%; year-to-date buybacks of 0.9 million shares for about $250 million.
- The Cigna Group 2026 Investor Day: edited transcript (Evanko, Perlberg, Holgerson, Kautzner, Andresen, Flaster, Dennison)
- New vision "Lead to One": personalization at scale for all customers, with the largest impact on people with complex conditions (8% of patients, 55% of health care spending). Three growth platforms: Specialty and Care (37% of enterprise earnings, up from 30%), Pharmacy Benefit Services (23%) and Cigna Healthcare (about 40%).
- Targets through 2030: 10% to 14% average annual adjusted EPS growth (6% to 9% operating income growth plus 4% to 5% from capital deployment), at least 10% EPS growth in 2027, about $50 billion of operating cash flow 2026-2030, and an adjusted EPS floor of $45 by 2030.
- "Accelerate to One": a $3 billion multiyear savings programme (2026-2030) through workflow automation and AI, talent, and supplier and vendor optimisation; part reinvested.
- Specialty and Care: 8% to 12% annual earnings growth, more than 40% of group earnings by 2030; Accredo about $80 billion revenue (about 40% from outside the group), access to over 330 limited distribution drugs; CuraScript about $25 billion, growing about 20% a year; about $20 billion of new distribution revenue by 2030.
- Cigna Healthcare: 6% to 9% earnings growth, 10.5% to 11.5% margins; Select market share from 8% to 10% by 2030; Health Sense AI clinical support model to cut inefficient care 10% by 2030; almost 10 million pharmacy-only lives as upside.
- Pharmacy Benefit Services: $140 billion business serving 117 million Americans; flat to 4% earnings growth; at least 50% of members on the rebate-free Signature model by end 2028, at similar margins.
- AI partnerships: Sierra (voice agents; Accredo agent handles over 40% of calls) and OpenAI (clinical AI, starting with oncology); AI "to augment but never to replace clinical expertise".
- Q2 2026 Cigna Group Earnings Call: edited transcript (Brian Evanko, Ann Dennison)
- First call with Brian Evanko as CEO: both Evernorth and Cigna Healthcare beat expectations; revenues $71.7 billion and adjusted EPS $7.78; full-year adjusted EPS guidance raised to at least $30.45, with 10% to 14% EPS growth still the frame for 2027.
- Clients' themes: affordability ("the most pronounced problem across the health care space"), personalization, and actionable clinical insights.
- Specialty and Care pre-tax earnings +22% to $1.1 billion on biosimilar and specialty generic adoption (over 80% penetration for newer specialty generics) and Shields; PBS earnings $609 million after large-client renewals and Signature investment.
- PBM selling season for 2027 is one of the strongest in years: 2026 retention over 97%, 2027 mid-90s or higher; new business secured exceeds the prior two seasons combined.
- Signature rebate-free model: Cigna Healthcare insured book in 2027, broad launch 2028, target margins around 4%; transition spend similar in 2027, then ramping down.
- Cigna Healthcare: revenues $11.8 billion (+10%), MCR 84.5%; medical cost trend "high single digit"; Select customers +5%; stop loss tracking over $8 billion of premiums; exit from ACA exchanges at end of 2026 with some stranded overhead.
- AI: Pharmacy Forward to cut time to therapy in half; AI care coordination to reach 20% more customers with emerging complex needs, saving about $2,000 a year per engaged customer.
Questions about The Cigna Group
What does The Cigna Group do?
It runs Evernorth Health Services, which covers pharmacy benefits (Express Scripts), specialty pharmacy (Accredo) and care services, and Cigna Healthcare, which provides employer medical plans and international health cover.
What is The Cigna Group's revenue?
Total revenues were $274,900 million in 2025, up 11%. Q2 2026 revenues were $71,668 million.
How many employees does The Cigna Group have?
Approximately 67,700 people at the end of 2025, about 88% of them in the United States.
What is The Cigna Group's strategy?
It targets 10% to 14% EPS growth through 2030 by growing specialty pharmacy, moving pharmacy benefits to the rebate-free Signature model, expanding employer plans in the Select market and using AI for productivity.
Who leads The Cigna Group?
Brian Evanko is President and Chief Executive Officer, and Ann Dennison is EVP and CFO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)